Publicação científica trimestral do CREMERJ - volume 3 - número 2 - 2024

81 Med. Ciên. e Arte , Rio de Janeiro, v.3, n.2, p.65-82, mai-ago 2024 Estado Atual do Tratamento do Câncer Colorretal Pedro Basilio 9. Chalabi M, Verschoor YL, Tan PB, Balduzzi S, Van Lent AU, Grootscholten C, Dokter S, Büller NV, Grotenhuis BA, Kuhlmann K, Burger JW, Huibregtse IL, Aukema TS, Hendriks ER, Oosterling SJ, Snaebjornsson P, Voest EE, Wessels LF, Beets-Tan RG, Van LeerdamME, Schumacher TN, van den Berg JG, Beets GL, Haanen JB. Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer. Niche-2 trial. N Engl J Med. 2024 Jun 6;390(21):1949-1958. 10. Del Paggio JC, Peng Y, Wei X, et al. Population-based study to re-evaluate optimal lymph node yield in colonic cancer. Br J Surg. 2017;104:1087-1096. 11. Basilio P, Fonseca LMB. Detecço de linfonodo-sentinela no cancer colorretal. Arq Gastroenterol, Sao Paulo, v.43, n.3: p.163-167, 2006. 12. Deijen CL, Vasmel JE, de Lange-de Klerk ESM, et al.; COLOR (COlon cancer Laparoscopic or Open Resection) Study Group. Ten-year outcomes of a randomised trial of laparoscopic versus open surgery for colon cancer. Surg Endosc. 2017;31:2607-2615. 13. Green BL, Marshall HC, Collinson F, et al. Long-term follow- up of the Medical Research Council CLASICC trial of conventional versus laparoscopically assisted resection in colorectal cancer. Br J Surg. 2013;100:75-82. 14. Cuk P, Kjær MD, Mogensen CB et al. Short-term outcomes in robot-assisted compared to laparoscopic colon cancer resections: a systematic review and meta-analysis. Surg Endosc, 2022; (36):32-46. 15. Seymour MT, Morton D. International FOxTROT Trial Investigators. FOxTROT: an international randomised controlled trial in 1052 patients (pts) evaluating neoadjuvant chemotherapy (NAC) for colon cancer. J Clin Oncol. 2019;15(suppl):3504-3504. 16. Karoui M, Rullier A, Piessen G, et al; for PRODIGE 22 investi- gators/collaborators. Perioperative FOLFOX 4 versus FOLFOX 4 plus cetuximab versus immediate surgery for high-risk stage II and III colon cancers: a phase II multicenter randomized controlled trial (PRODIGE 22). Ann Surg. 2020;271:637-645. 17. Jensen LH, Kjaer ML, Larsen FO et al; Phase III randomized clinical trial comparing the efficacy of neoadjuvant chemotherapy and standard treatment in patients with locally advanced colon cancer: The NeoCol trial. JCO 2023;41,17 suppl. LBA3503. 18. Starling N, Newmann K, Colwell B, Strickler JH; AZUR-2, a phase III, open-label, randomized study of perioperative dostarlimab monotherapy vs standard of care in previously untreated patients with T4N0 or stage III dMMR/MSI-H resectable colon cancer. JCO, 2024;42, 3_suppl, TPS240 19. Krishnamurty DM, Hawkins AT, Wells KO, et al. Neoadjuvant radiation therapy in locally advanced colon cancer: a cohort analysis. J Gastrointest Surg. 2018;22:906-912. 20. Hogan J, Samaha G, Burke J, et al. Emergency presenting colon cancer is an independent predictor of adverse disease-free survival. Int Surg. 2015;100:77-86. 21. Lahaye MJ, Engelen SM, Nelemans PJ, et al. Imaging for pre- dicting the risk factors–the circumferential resection margin and nodal disease–of local recurrence in rectal cancer: a meta-analysis. Semin Ultrasound CT MR. 2005;26:259-268. 22. Atallah S, Albert M & Larach S. Transanal minimally invasive surgery: a giant leap forward. Surg Endosc 2010 24:2200-2205. 23. Smits LJ, Van Lieshout AS, Grüter AAJ, et all. Multidisciplinary management of early rectal cancer – The role of surgical local excision in current and future clinical practice, Surgical Oncology 2020 (40) #101687. 24. Clancy C, Flanagan M, Marinello F, O’Neill BD, McNamara D, Burke JP. Comparative oncologic outcomes of upper third rectal cancers: a meta-analysis. Clin Colorectal Cancer. 2019;18:e361-e367. 25. Peeters KC, Marijnen CA, Nagtegaal ID, et al; Dutch Colorectal Cancer Group. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246:693-701.